Search
for
Sort by
Research 91–120 of 179
- Teneligliptin-induced hair loss: A case report
- Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS
- Treatment of Nonclassic 11-Hydroxylase Deficiency with Ashwagandha Root
- Overcoming Curcumin's Limitations: Synthetic Derivatives in Diabetes and Cancer Management
- Inhibition of CISD1 attenuates cisplatin-induced hearing loss in mice via the PI3K and MAPK pathways
- MON-369 Treatment of Nonclassic 11-Hydroxylase Deficiency with "Hair, Skin, and Nails," an Over-the-Counter, Insulin Sensitizing Vitamin/Mineral Supplement
- Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ
- 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
- Treatment options for polycystic ovary syndrome
- Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline
- New developments in our understanding of acne pathogenesis and treatment
- Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
- Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth
- The pathogenesis and treatment of polycystic ovary syndrome: What’s new?
- Lichen Planopilaris Treated With a Peroxisome Proliferator–Activated Receptor γ Agonist
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hyperandrogenic Disorders
- Targeting Wnt/β-catenin signaling and its interplay with TGF-β and Notch signaling pathways for the treatment of chronic wounds
- Insulin Resistance and Skin Diseases
- Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the ‘future’ in dermatology therapeutics?
- Novel Fish Oil-based Bigel System for Controlled Drug Delivery and its Influence on Immunomodulatory Activity of Imiquimod Against Skin Cancer
- PPAR-<i>γ</i> Agonists and Their Role in Primary Cicatricial Alopecia
- Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome
- When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
- Repurposing existing drugs for COVID-19: an endocrinology perspective
- Exercise activates the PI3K-AKT signal pathway by decreasing the expression of 5α-reductase type 1 in PCOS rats
- Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
- Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome
- Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review
- PPAR‐γ signalling as a key mediator of human hair follicle physiology and pathology
- Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations